Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2022

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets, net for each of 2022 and 2021 is as follows:


	Year Ended March 31, 2022
(In thousands)	Indefinite- Lived Tradenames		Finite-Lived Tradenames and Customer Relationships		Totals
Gross Carrying Amounts
Balance – March 31, 2021	$	2,281,988	$	389,347	$	2,671,335
Additions(a)	195,900		47,642		243,542


Tradename impairment	—		(1,700)		(1,700)
Effects of foreign currency exchange rates	(1,329)		885		(444)
Balance – March 31, 2022	$	2,476,559	$	436,174	$	2,912,733

Accumulated Amortization
Balance – March 31, 2021	$	—	$	195,606	$	195,606
Additions	—		21,499		21,499
Tradename impairment	—		(983)		(983)
Effects of foreign currency exchange rates	—		(24)		(24)
Balance – March 31, 2022	$	—	$	216,098	$	216,098

Intangible assets, net – March 31, 2022	$	2,476,559	$	220,076	$	2,696,635

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,391,517	$	198,353	$	2,589,870
International OTC Healthcare	85,042		21,723		106,765

Intangible assets, net – March 31, 2022	$	2,476,559	$	220,076	$	2,696,635

(a) On July 1, 2021, we completed the acquisition of certain assets from Akorn (see Note 2) and on December 15, 2021 our Australian subsidiary acquired the rights to the Zaditen brand in certain territories from Novartis Pharma AG. In connection with these acquisitions, we allocated $225.4 million to intangible assets based on our preliminary analysis for Akorn and $18.1 million for Zaditen.


	Year Ended March 31, 2021
(In thousands)	Indefinite- Lived Tradenames		Finite-Lived Tradenames and Customer Relationships		Totals
Gross Carrying Amounts
Balance – March 31, 2020	$	2,265,331	$	389,801	$	2,655,132



Tradename impairment	—		(1,186)		(1,186)
Effects of foreign currency exchange rates	16,657		732		17,389
Balance – March 31, 2021	$	2,281,988	$	389,347	$	2,671,335

Accumulated Amortization
Balance – March 31, 2020	$	—	$	175,741	$	175,741
Additions			19,580		19,580

Effects of foreign currency exchange rates	—		285		285
Balance – March 31, 2021	$	—	$	195,606	$	195,606

Intangible assets, net – March 31, 2021	$	2,281,988	$	193,741	$	2,475,729

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,195,617	$	190,462	$	2,386,079
International OTC Healthcare	86,371		3,279		89,650

Intangible assets, net – March 31, 2021	$	2,281,988	$	193,741	$	2,475,729

Schedule of Expected Amortization Expense

At March 31, 2022, finite-lived intangible assets are expected to be amortized over their estimated useful lives, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):


(In thousands)
Year Ending March 31,	Amount
2023	$	22,576
2024	22,533
2025	20,479
2026	18,232
2027	16,591
Thereafter	119,665
	$	220,076